Skip to content

A single-case randomized controlled study of Huaiqihuang granules in treatment of proteinuria in IgA nephropathy

A single-case randomized controlled study of Huaiqihuang granules in treatment of proteinuria in IgA nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049833
Enrollment
Unknown
Registered
2021-08-10
Start date
2021-08-10
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

control group:Telmisartan tablets
Experimental group:Huai Qi Huang Granules+Telmisartan tablets

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis was IgA nephropathy, and the pathologic reports of renal perforation were reported in all cases; 2. aged 18 to 50 years; 3. Moderate proteinuria(24-hour urinary protein quantity is between 1.0-2.5g)accompanied or not accompanied by microscopic hematuria; 4. CKD1-2 (GFR>=60ml/min/1.73m2); 5. TCM syndrome differentiation accords with deficiency of Qi and Yin 6. Non-dialysis patients with infection, acidosis, electrolyte disturbance, hypertension and other aggravating factors are effectively controlled and the condition is stable. The BP is be effectively controlled in 140/90mmHg,Potassium is in the normal range; 7. Voluntarily accept this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.The age is less than 18 years old or more than 50 years old; 2.GFR<=60ml/min/1.73m2; 3.Patients with mild or severe proteinuria (24-hour urine protein quantification less than 1.0g or more than 2.5g) and nephrotic syndrome; 4.Various secondary IgA nephropathy; 5.Those who have used glucocorticoids, immunosuppressants or Tripterygium wilfordii preparation within three months; 6.Hypotension patients with blood pressure <=90/60mmHg; 7.Severe diseases of the heart, brain, liver and hematopoietic system, or other serious diseases affecting their survival; 8.Unilateral or bilateral renal artery stenosis; 9.Breast-feeding, pregnant or planning pregnancy during the study period; 10.Attending to participate in another clinical researcher.

Design outcomes

Primary

MeasureTime frame
Urine protein quantitation for 24 hours;

Secondary

MeasureTime frame
Routine urine;Traditional Chinese Medicine symptom score;renal function;Blood fat;Routine blood;Liver function;

Countries

China

Contacts

Public ContactZhang Yu

Xiyuan Hospital, China Academy of Chinese Medical Sciences

zhangyu8225@126.com+86 13611079831

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026